{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:48:07Z","timestamp":1782276487333,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04868-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:06:16Z","timestamp":1782212776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics, treatment patterns, healthcare resource use, and costs among adult patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas in the United States"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6782","authenticated-orcid":false,"given":"Mavis","family":"Obeng-Kusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayo","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Cunnington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"4868_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/B978-0-444-64076-5.00051-X","volume":"148","author":"PJ Cimino","year":"2018","unstructured":"Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799\u2013811. https:\/\/doi.org\/10.1016\/B978-0-444-64076-5.00051-X.","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"4868_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","volume":"103","author":"KI Ly","year":"2019","unstructured":"Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am. 2019;103(6):1035\u201354. https:\/\/doi.org\/10.1016\/j.mcna.2019.07.004.","journal-title":"Med Clin North Am Nov"},{"issue":"1","key":"4868_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"T-SJ Lee","year":"2023","unstructured":"Lee T-SJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: A systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292. https:\/\/doi.org\/10.1186\/s13023-023-02911-2.","journal-title":"Orphanet J Rare Dis Sep"},{"issue":"4","key":"4868_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","volume":"159","author":"R Nguyen","year":"2011","unstructured":"Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. J Pediatr. 2011;159(4):652\u201355.E2. https:\/\/doi.org\/10.1016\/j.jpeds.2011.04.008.","journal-title":"J Pediatr Oct"},{"issue":"3","key":"4868_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.bpo.0000217719.10728.39","volume":"26","author":"AH Crawford","year":"2006","unstructured":"Crawford AH, Schorry EK. Neurofibromatosis update. J Pediatr Orthop. 2006;26(3):413\u201323. https:\/\/doi.org\/10.1097\/01.bpo.0000217719.10728.39.","journal-title":"May-Jun"},{"issue":"12","key":"4868_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20(12):1643\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noy067.","journal-title":"Neuro Oncol Nov"},{"issue":"1","key":"4868_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","volume":"12","author":"K Jett","year":"2010","unstructured":"Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1\u201311. https:\/\/doi.org\/10.1097\/GIM.0b013e3181bf15e3.","journal-title":"Genet Med Jan"},{"key":"4868_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/b978-0-444-62702-5.00004-4","volume":"132","author":"JL Anderson","year":"2015","unstructured":"Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75\u201386. https:\/\/doi.org\/10.1016\/b978-0-444-62702-5.00004-4.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"4868_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7181\/acfs.2022.00633","volume":"23","author":"J Choi","year":"2022","unstructured":"Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: Pathophysiology and treatment. Arch Craniofac Surg. 2022;23(1):6\u201316. https:\/\/doi.org\/10.7181\/acfs.2022.00633.","journal-title":"Arch Craniofac Surg Feb"},{"issue":"1","key":"4868_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-7819-3-6","volume":"3","author":"RE Friedrich","year":"2005","unstructured":"Friedrich RE, Schmelzle R, Hartmann M, F\u00fcnsterer C, Mautner V-F. Resection of small plexiform neurofibromas in neurofibromatosis type 1 children. World J Surg Oncol. 2005;3(1):6. https:\/\/doi.org\/10.1186\/1477-7819-3-6.","journal-title":"World J Surg Oncol Jan"},{"issue":"11","key":"4868_CR11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344. https:\/\/doi.org\/10.1093\/neuonc\/noac146.","journal-title":"Neuro Oncol Nov"},{"issue":"4","key":"4868_CR12","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","volume":"6","author":"I Solares","year":"2021","unstructured":"Solares I, Vi\u00f1al D, Morales-Conejo M, Rodriguez-Salas N, Feliu J. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: A comprehensive review. ESMO Open. 2021;6(4):100223. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100223.","journal-title":"ESMO Open Aug"},{"issue":"3","key":"4868_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40262-020-00967-y","volume":"60","author":"O Campagne","year":"2021","unstructured":"Campagne O, Yeo KK, Fangusaro J, Stewart CF. Clinical pharmacokinetics and pharmacodynamics of selumetinib. Clin Pharmacokinet. 2021;60(3):283\u2013303. https:\/\/doi.org\/10.1007\/s40262-020-00967-y.","journal-title":"Clin Pharmacokinet Mar"},{"issue":"5","key":"4868_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/03007995.2021.1900089","volume":"37","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Maitra A, Choudhury S. Selumetinib: The first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. Curr Med Res Opin. 2021;37(5):789\u201394. https:\/\/doi.org\/10.1080\/03007995.2021.1900089.","journal-title":"Curr Med Res Opin May"},{"key":"4868_CR15","unstructured":"Prescribing Information - KOSELUGO (selumetinib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213756s004lbl.pdf.\u00a0Accessed 6 Dec 2024."},{"key":"4868_CR16","unstructured":"FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas.\u00a0Accessed 6 Dec 2024."},{"key":"4868_CR17","unstructured":"FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform.\u00a0Accessed 3 Feb 2026."},{"issue":"15","key":"4868_CR18","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1912735.","journal-title":"N Engl J Med"},{"issue":"15","key":"4868_CR19","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey D, Demko S, Sinha A, et al. FDA approval summary: Selumetinib for plexiform neurofibroma. Clin Cancer Res. 2021;27(15):4142\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-5032.","journal-title":"Clin Cancer Res Aug"},{"key":"4868_CR20","unstructured":"ClinicalTrials.gov. Efficacy and safety of selumetinib in adults with NF1 who have symptomatic, inoperable plexiform neurofibromas (KOMET). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04924608. Accessed\u00a06 Dec 2024."},{"issue":"10496","key":"4868_CR21","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GOS, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): A multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405(10496):2217\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(25)00986-9.","journal-title":"Lancet Jun"},{"issue":"1","key":"4868_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","volume":"31","author":"AM Gross","year":"2025","unstructured":"Gross AM, O\u2019Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: A phase 2 trial. Nat Med. 2025;31(1):105\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03361-4.","journal-title":"Nat Med Jan"},{"issue":"6","key":"4868_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43(6):716\u201329. https:\/\/doi.org\/10.1200\/JCO.24.01034.","journal-title":"J Clin Oncol Feb"},{"key":"4868_CR24","unstructured":"ClinicalTrials.gov. Phase II study of binimetinib in children and adults with NF1 plexiform neurofibromas (NF108-BINI). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03231306.\u00a0Accessed 6 Dec 2024."},{"key":"4868_CR25","unstructured":"ClinicalTrials.gov. Study of Tasigna\u00ae\/\u200bnilotinib (AMN107) in neurofibromatosis (NF1) patients with plexiform neurofibromas. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01275586.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR26","unstructured":"ClinicalTrials.gov. Use of RAD001 as monotherapy in the treatment of neurofibromatosis 1 related internal plexiform neurofibromas (NFitor). Available from: https:\/\/clinicaltrials.gov\/study\/NCT01412892.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR27","unstructured":"ClinicalTrials.gov. Safety and pharmacokinetics of cobimetinib in pediatric and young adult participants with previously treated solid tumors (iMATRIXcobi). Available from: https:\/\/clinicaltrials.gov\/study\/NCT02639546.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR28","unstructured":"ClinicalTrials.gov. PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00253474.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR29","unstructured":"ClinicalTrials.gov. Phase II study of Gleevec\/\u200bimatinib mesylate (STI-571, NCS 716051) in neurofibromatosis (NF1) patients with plexiform neurofibromas. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01673009.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR30","unstructured":"ClinicalTrials.gov. Study of Sutent\u00ae\/\u200bsunitinib (SU11248) in subjects with NF-1 plexiform neurofibromas. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01402817.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR31","unstructured":"ClinicalTrials.gov. Cabozantinib for plexiform neurofibromas (PN) in subjects with NF1 in children and adults (NF105-CABO). Available from: https:\/\/clinicaltrials.gov\/study\/NCT02101736.\u00a0Accessed 11 Dec 2024."},{"key":"4868_CR32","unstructured":"ClinicalTrials.gov. Study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants With neurofibromatosis type 1. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04954001.\u00a0Accessed 11 Dec 2024."},{"issue":"4","key":"4868_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/03007995.2024.2322698","volume":"40","author":"Y Yoshida","year":"2024","unstructured":"Yoshida Y, Tozawa K, Koto R, et al. Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Curr Med Res Opin. 2024;40(4):723\u201331. https:\/\/doi.org\/10.1080\/03007995.2024.2322698.","journal-title":"Curr Med Res Opin Apr"},{"issue":"7","key":"4868_CR34","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","volume":"25","author":"LJ Klesse","year":"2020","unstructured":"Klesse LJ, Jordan JT, Radtke HB, et al. The use of MEK inhibitors in neurofibromatosis type 1\u2013associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109\u201316. https:\/\/doi.org\/10.1634\/theoncologist.2020-0069.","journal-title":"Oncologist Jul"},{"issue":"3","key":"4868_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/nop\/npac014","volume":"9","author":"TA Gregory","year":"2022","unstructured":"Gregory TA, Molina PSB, Phillips GD, Henson JW. Impact of neurofibromatosis type 1 in an adult community population. Neurooncol Pract. 2022;9(3):229\u201335. https:\/\/doi.org\/10.1093\/nop\/npac014.","journal-title":"Neurooncol Pract Feb"},{"key":"4868_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/phmt.S265690","volume":"11","author":"X Yang","year":"2020","unstructured":"Yang X, Desai K, Agrawal N, et al. Treatment, resource use and costs among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Pediatric Health Med Ther. 2020;11:421\u20138. https:\/\/doi.org\/10.2147\/phmt.S265690.","journal-title":"Pediatric Health Med Ther Oct"},{"issue":"9","key":"4868_CR37","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/03007995.2021.1940907","volume":"37","author":"X Yang","year":"2021","unstructured":"Yang X, Desai K, Agrawal N, et al. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: A retrospective database analysis of a medicaid population. Curr Med Res Opin. 2021;37(9):1555\u201361. https:\/\/doi.org\/10.1080\/03007995.2021.1940907.","journal-title":"Curr Med Res Opin Sep"},{"issue":"3","key":"4868_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/pbc.22827","volume":"56","author":"T Hummel","year":"2011","unstructured":"Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1\u2010related plexiform neurofibroma to high\u2010dose carboplatin. Pediatr Blood Cancer. 2011;56(3):488\u201390. https:\/\/doi.org\/10.1002\/pbc.22827.","journal-title":"Pediatr Blood Cancer Mar"},{"key":"4868_CR39","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.esmorc.2025.100016","volume":"3","author":"DJ Benjamin","year":"2025","unstructured":"Benjamin DJ. Emerging therapies for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. ESMO Rare Cancers. 2025;3:100016. https:\/\/doi.org\/10.1016\/j.esmorc.2025.100016.","journal-title":"ESMO Rare Cancers Sep"},{"issue":"7 Suppl 1","key":"4868_CR40","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1097\/MLR.0b013e31819c95aa","volume":"47","author":"GF Riley","year":"2009","unstructured":"Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51\u201355. https:\/\/doi.org\/10.1097\/MLR.0b013e31819c95aa.","journal-title":"Med Care Jul"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04868-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04868-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04868-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:15:32Z","timestamp":1782274532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04868-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4868"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04868-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was considered exempt research under 45 CFR \u00a7\u00a046.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7\u00a0164.514. The study was conducted according to the standards of Good Pharmacoepidemiology Practice (GPP) and all applicable federal, state, and local laws, rules, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"XY and MO are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock\/stock options in Merck & Co., Inc., Rahway, NJ, USA. TD and AA are employees of Alexion, AstraZeneca Rare Disease and own stock\/stock options. JTJ is an independent consultant of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Akeila Bio, Alexion Pharmaceuticals, AstraZeneca, Navio Theragnostics, Recursion Pharmaceuticals, Shepherd Therapeutics, Springworks Therapeutics, is an employee of University of Texas Southwestern Medical Center, and owns stock\/stock options from Akeila Bio, Khora TX, Navio Theragnostics, and Shepherd Therapeutics. MC, QL, DL, GC, and MSD are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, which funded the development and conduct of this study and manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}